NASDAQ : ANTX
AN2 Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 4.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 170.95M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 12.17M | 13.34M | 14.07M | 14.76M | 12.75M | 4.67M |
| Research & Development | 26.64M | 24.77M | 40.49M | 54.87M | 29.51M | 16.91M |
| Operating Expenses | 38.81M | 38.11M | 54.55M | 69.64M | 42.26M | 21.57M |
| Operating Income | -38.81M | -38.11M | -54.55M | -69.64M | -42.26M | -21.57M |
| Interest & Investment Income | 2.54M | 2.93M | 5.47M | 4.86M | 69.00K | |
| Currency Exchange Gain (Loss) | -38.00K | |||||
| Other Non Operating Income (Expenses) | 1.00K | 1.00K | 43.00K | 1.31M | ||
| EBT Excluding Unusual Items | -36.28M | -35.17M | -49.09M | -64.73M | -40.96M | -21.54M |
| Merger & Restructuring Charges | -2.23M | |||||
| Pretax Income | -36.28M | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
| Net Income | -36.28M | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
| Preferred Dividends & Other Adjustments | 1.82M | 6.51M | ||||
| Net Income to Common | -36.28M | -35.17M | -51.32M | -64.73M | -42.78M | -28.06M |
| Shares Outstanding (Basic) | 34.88M | 30.22M | 29.83M | 23.60M | 15.34M | 2.64M |
| Shares Outstanding (Diluted) | 34.88M | 30.22M | 29.83M | 23.60M | 15.34M | 2.64M |
| EPS (Basic) | -1.04 | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
| EPS (Diluted) | -1.04 | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
| EBIT | -38.81M | -38.11M | -54.55M | -69.64M | -42.26M | -21.57M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 44.32M | 19.94M | 21.35M | 15.65M | 27.22M | 12.10M |
| Short-Term Investments | 34.07M | 38.06M | 62.27M | 91.65M | 68.84M | 46.46M |
| Cash & Short-Term Investments | 78.39M | 58.00M | 83.62M | 107.30M | 96.06M | 58.55M |
| Other Receivables | 300.00K | 900.00K | 300.00K | 1.40M | ||
| Receivables | 300.00K | 900.00K | 300.00K | 1.40M | ||
| Prepaid Expenses | 1.30M | 1.04M | 2.34M | 1.81M | 2.51M | 1.55M |
| Other Current Assets | 53.00K | |||||
| Total Current Assets | 79.99M | 59.94M | 86.26M | 110.51M | 98.62M | 60.11M |
| Long-Term Investments | 1.47M | 2.01M | 5.02M | 27.19M | 3.22M | 3.49M |
| Long-Term Deferred Charges | 1.72M | |||||
| Other Long-Term Assets | 216.00K | 804.00K | 1.04M | 720.00K | ||
| Total Assets | 81.68M | 61.95M | 92.09M | 138.74M | 102.56M | 65.32M |
| Accounts Payable | 1.97M | 3.02M | 3.32M | 2.68M | 2.12M | 1.06M |
| Accrued Expenses | 2.84M | 4.47M | 6.13M | 10.70M | 5.00M | 2.00M |
| Current Portion of Leases | 53.00K | |||||
| Other Current Liabilities | 776.00K | 1.23M | 791.00K | 668.00K | 6.00K | 330.00K |
| Total Current Liabilities | 5.58M | 8.72M | 10.24M | 14.04M | 7.19M | 3.40M |
| Other Long-Term Liabilities | 170.00K | 170.00K | 2.00K | 13.00K | ||
| Total Liabilities | 5.75M | 8.89M | 10.24M | 14.04M | 7.19M | 3.41M |
| Additional Paid-In Capital | 335.11M | 293.95M | 287.59M | 278.88M | 185.47M | |
| Retained Earnings | -259.16M | -240.95M | -205.78M | -154.46M | -89.72M | -47.38M |
| Comprehensive Income & Other | -23.00K | 57.00K | 31.00K | 275.00K | -374.00K | -27.00K |
| Total Common Equity | 75.92M | 53.06M | 81.85M | 124.70M | 95.37M | -47.41M |
| Shareholders' Equity | 75.92M | 53.06M | 81.85M | 124.70M | 95.37M | 61.91M |
| Total Liabilities & Equity | 81.68M | 61.95M | 92.09M | 138.74M | 102.56M | 65.32M |
| Total Debt | 53.00K | |||||
| Net Cash (Debt) | 78.39M | 58.00M | 83.62M | 107.30M | 96.01M | 58.55M |
| Net Cash Per Share | 2.25 | 1.92 | 2.80 | 4.55 | 6.26 | 22.20 |
| Filing Date Shares Outstanding | 37.74M | 35.94M | 30.10M | 29.77M | 19.40M | 2.73M |
| Total Common Shares Outstanding | 36.31M | 27.41M | 29.92M | 29.74M | 19.40M | 2.73M |
| Working Capital | 74.41M | 51.22M | 76.02M | 96.46M | 91.44M | 56.71M |
| Book Value Per Share | 2.09 | 1.94 | 2.74 | 4.19 | 4.92 | -17.36 |
| Tangible Book Value | 75.92M | 53.06M | 81.85M | 124.70M | 95.37M | -47.41M |
| Tangible Book Value Per Share | 2.09 | 1.94 | 2.74 | 4.19 | 4.92 | -17.36 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -36.28M | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
| Loss (Gain) From Sale of Investments | -503.00K | -1.07M | -3.28M | -2.85M | -692.00K | 53.00K |
| Stock-Based Compensation | 4.63M | 6.25M | 8.34M | 8.41M | 4.39M | 974.00K |
| Other Operating Activities | 53.00K | 77.00K | ||||
| Change in Accounts Payable | -495.00K | -296.00K | 641.00K | 553.00K | 2.50M | 417.00K |
| Change in Other Net Operating Assets | 1.96M | 460.00K | -3.64M | 5.28M | 1.22M | -385.00K |
| Operating Cash Flow | -30.68M | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
| Investment in Securities | 17.91M | 28.31M | 54.59M | -43.28M | -21.77M | -50.02M |
| Investing Cash Flow | 17.91M | 28.31M | 54.59M | -43.28M | -21.77M | -50.02M |
| Issuance of Common Stock | 39.11M | 113.00K | 372.00K | 84.99M | 70.37M | 11.00K |
| Repurchase of Common Stock | -11.00K | |||||
| Other Financing Activities | -248.00K | -1.21M | ||||
| Financing Cash Flow | 38.87M | 113.00K | 372.00K | 84.99M | 70.36M | 78.53M |
| Net Cash Flow | 26.10M | -1.41M | 5.70M | -11.57M | 15.12M | 8.03M |
| Levered Free Cash Flow | -18.02M | -18.38M | -29.00M | -28.85M | -19.30M | -11.96M |
| Unlevered Free Cash Flow | -18.02M | -18.38M | -29.00M | -28.85M | -19.30M | -11.96M |
| Change in Working Capital | 1.46M | 164.00K | -3.00M | 5.83M | 3.72M | 32.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 170.95M | 31.24M | 41.23M | 609.40M | 184.91M | |
| Enterprise Value | 92.56M | -30.68M | -52.19M | 485.58M | 80.60M | |
| Last Close Price | 4.53 | 1.14 | 1.38 | 20.49 | 9.53 | |
| PB Ratio | 2.17 | 0.59 | 0.50 | 4.89 | 1.94 | |
| P/TBV Ratio | 2.25 | 0.59 | 0.50 | 4.89 | 1.94 | |
| Debt / Equity Ratio | 0.00 | |||||
| Net Debt / Equity Ratio | -1.03 | -1.09 | -1.02 | -0.86 | -1.01 | -0.95 |
| Quick Ratio | 14.09 | 6.75 | 8.20 | 7.74 | 13.37 | 17.25 |
| Current Ratio | 14.32 | 6.87 | 8.43 | 7.87 | 13.72 | 17.70 |
| Return on Equity (ROE) | -50.12% | -52.14% | -49.69% | -58.83% | -52.08% | -66.64% |
| Return on Assets (ROA) | -30.80% | -30.93% | -29.54% | -36.07% | -31.47% | -38.77% |
| Return on Capital Employed (ROCE) | -51.00% | -71.60% | -66.70% | -55.80% | -44.30% | -34.80% |
| Earnings Yield | -22.96% | -112.60% | -124.47% | -10.62% | -22.15% | |
| Buyback Yield / Dilution | -16.31% | -1.30% | -26.39% | -53.85% | -481.46% | -2.71% |